Nanomedicine Global Market Report 2024

Nanomedicine involves the application of nanotechnology in the field of medicine. It encompasses substances with sizes ranging from 1 to 100 nanometers, designed to precisely target tumor cells or critical immune cells. Nanomedicine serves as a crucial tool for personalized, targeted, and regenerative medicine, facilitating the delivery of enhanced new drugs, treatments, and implantable devices to both clinicians and patients.

The primary types of nanomedicine include nanoparticles, nanoshells, nanotubes, nanodevices, and others. Nanoparticles, specifically ultrafine particles typically between 1 and 100 nanometers in diameter, are commonly used in the production of medicines and drugs. Nanomedicine operates across different modalities such as diagnostics and treatments, finding applications in clinical oncology, infectious diseases, clinical cardiology, orthopedics, and other medical fields.

The nanomedicine market research report is one of a series of new reports that provides nanomedicine market statistics, including nanomedicine industry global market size, regional shares, competitors with a nanomedicine market share, detailed nanomedicine market segments, market trends and opportunities, and any further data you may need to thrive in the nanomedicine industry. This nanomedicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nanomedicine market size has grown rapidly in recent years. It will grow from $292.72 billion in 2023 to $335.25 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth observed in the historical period can be attributed to factors such as an increased understanding of molecular biology, a growing incidence of chronic diseases, the demand for targeted drug delivery systems, the expansion of nanoparticle imaging technologies, and a rising aging population.

The nanomedicine market size is expected to see rapid growth in the next few years. It will grow to $594.63 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%. The anticipated growth in the forecast period can be attributed to the ongoing expansion of nanotechnology research, increased investments in nanomedicine research and development, a growing focus on personalized medicine, the broadening applications of nanomedicine in cancer treatment, and the integration of nanomedicine in infectious disease therapeutics. Major trends expected in the forecast period include the development of multifunctional nanoparticles for therapeutics and imaging, an emphasis on nanoparticle-based diagnostics and imaging agents, the application of nanomedicine in regenerative medicine, a growing use of nanomedicine in targeted therapy for neurological disorders, and increased collaboration and partnerships in nanomedicine research and commercialization.

The anticipated increase in the prevalence of complex and chronic diseases worldwide is expected to contribute to the growth of the nanomedicine market in the forecast period. Nanomedicine is becoming increasingly integral in treating chronic conditions such as cardiovascular disorders, diabetes, cancer, and dementia, facilitating the rapid metabolism of drugs within the body. Notably, Alzheimer's Disease International reports that over 50 million people globally suffer from dementia, a number projected to double every 20 years, reaching 80 million by 2030 and 152 million by 2050. The global cancer burden is also predicted to escalate to 28.4 million new cases in 2040. The escalating burden of chronic diseases is poised to drive demand for effective therapeutic treatments based on nanomedicine, thereby fostering the growth of the nanomedicine market.

The growing demand for personalized medicine is expected to propel the nanomedicine market's growth. Personalized medicine, an innovative approach tailoring medical decisions and interventions to individual patients, holds the promise of improving outcomes and treatment efficacy through cutting-edge technology. Reports from October 2022 indicate more than 75,000 genetic testing products and 300 personalized medicines. This increasing demand for personalized medicine is a key driver behind the growth of the nanomedicine market.

Major players in the nanomedicine market are concentrating on innovative products, such as the dynapro zetastar, to enhance their market presence. This advanced instrument enables simultaneous measurements of dynamic and static light scattering, as well as dynamic and electrophoretic light scattering (DLS/SLS/ELS). For instance, Waters Corporation, a US-based analytical laboratory instruments and equipment company, launched the dynapro zetastar for nanoparticle analysis in September 2023. The instrument aids in the precise development of complex biologics by combining multiple light scattering techniques, offering adaptive data capture, automatic data quality assessment, and increased sensitivity and speed of measurements while using minimal sample volumes. The unique flow cell design allows connection to an autosampler, significantly enhancing laboratory productivity and efficiency by enabling unattended measurements for extended periods.

Innovative technologies, such as optical technology, are being employed by major companies in the nanomedicine market to drive revenues. Corning Incorporated, a US-based technology company, introduced corning videodrop in September 2023 - an optical technique measuring the size and concentration of nanoparticles using interferometric microscopy. Videodrop is reliable, quick, and easy to use, with a label-free sample preparation process. The user-friendly software interface ensures smooth operation, and the method allows the quantification of concentration and size distribution without labeling. Viral vectors, including lentivirus, retrovirus, adenovirus, and extracellular vesicles (EVs), within the diameter range of 80-500 nanometers, can be physically titrated using this approach. The Videodrop technique serves as an effective in-process control during the purification process.

In August 2021, Sanofi S. A., a France-based pharmaceutical and healthcare company, acquired Translate Bio, Inc., for $3.2 billion. This strategic move accelerates Sanofi's ongoing vaccination programs, enhances the mRNA Center of Excellence, and enables exploration of additional therapeutic fields. Translate Bio, Inc., a US-based biopharmaceutical company, brings valuable mRNA technology and expertise, advancing Sanofi's research capabilities in this promising technology for developing vaccines and treatments. The acquisition strengthens Sanofi's position in the rapidly evolving field of mRNA technology, allowing exploration of potential game-changing drugs for various conditions.

Major companies operating in the in the nanomedicine market report are Pfizer Inc., Ablynx NV, Amgen Inc., Arrowhead Research Inc., Bio-Gate AG, Celgene Corporation, F. Hoffmann-La Roche AG, GE Healthcare, Gilead Sciences Inc., Merck AG, Nanospectra Biosciences, Nanotherapeutics Inc., NanoViricides Inc, Novartis AG, Sanofi S. A., Abraxis Bioscience Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., AuraSense Therapeutics LLC, BIND Therapeutics Inc., Camurus AB, Cerulean Pharma Inc., CytImmune Sciences, Fujifilm Holdings, Nanobiosym Inc., Nanobiotix SA, Nanogen Inc., Nanomix Crop., Nanoparticle BioChem Inc., Nanospective Inc., Nanosphere Health Sciences Inc., Nanosys Inc., PerkinElmer Inc., Selecta Biosciences Inc., Sigma-Aldrich Co. LLC

North America was the largest region in the nanomedicine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanomedicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the nanomedicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The nanomedicine market consists of sales of gold, silica, iron oxide, polymeric, liposomes, and micelles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.